AFFILIATIONS
1 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
2 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
3 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
4 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
5 Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
6 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
7 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
8 Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States
9 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
10 Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, United States
11 Icahn School of Medicine at Mount Sinai, New York, United States
12 Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, United States
13 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
14 Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States
15 Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States
16 Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, United States
17 Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, United States
18 Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, United States
19 Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, United States
20 National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, United States
21 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
22 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
23 Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States
24 Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, United States
25 Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
ABSTRACT
Introduction: Different cell types tolerate acquired UBA1 mutations, etiologic for VEXAS syndrome, differentially. Clinical manifestations follow these aberrations: myeloid driven inflammation, marrow failure with anemia, opportunistic infections from depleted lymphocytes and monocytes, and plasma cell disorders (PCD), frequently with t(11;14) rearrangement. How B cell development is impacted in VEXAS is not well understood.
Methods: Patients with canonical somatic UBA1 mutations (M41L/T/V or splice site) enrolled in an NIH observational trial (NCT05012111) or evaluated at Mayo Clinic were included. UBA1 mutations were assessed by error-corrected sequencing (ECS) of sorted CD138+ cells from patients with PCD and by reanalysis of single-cell DNA sequencing from patients without PCD. Single-cell RNA sequencing (scRNA-seq) with B-cell receptor (BCR) sequencing compared patients without PCD with healthy donors (HD). PCD characteristics were determined using International Myeloma Working Group criteria.
Results: Marrow scRNA-seq/BCR from 4 VEXAS patients without PCD and 4 HD was assessed: B cell numbers were low in VEXAS compared to HD while PC numbers were equivalent. PCs in VEXAS demonstrated higher cell cycling (G2M checkpoint, MYC targets) and inflammation/immune response related pathways (IFN-α/γ) compared to HD. To explore how marrow inflammation contributes to PC expansion, we plotted upregulated genes in G2M checkpoint and IFN pathway. CCND1, encoding cyclin D1, and ISG15, in the IFN pathway, are functionally connected in the gene network. Compared to HD, there were stronger cell-cell interactions between pPC and myeloid cells. Frequent ligand-receptor pairs interacting between pPC and other cell types in VEXAS include APRIL-BCMA and PECAM1-CD38 with myeloid cells.
We next focused on clonal PCs: PCs within the dominant BCR clonotype were designated clonal PCs (cPC; n=212), and all remaining were designated polyclonal (pPC; n=1063). Most cPC were in late stage of plasma cell differentiation by pseudotime analysis. Majority of PCs were wild-type, and UBA1 mutated cells were equally divided among pPC and cPC. Due to the small numbers of UBA1 mutant cells and limited genotyping efficiency, further analysis was limited. ECS in PCD patients (variant allele frequency [VAF]: 10 - 44%) and scDNA-seq in patients without PCD orthogonally validated PCs to have UBA1 mutations.
Clinically, among 192 patients, 33 (17%) had PCD (MGUS, n=25; MM/SMM, n=8). PCD and non-PCD cohorts did not differ in demographics, VEXAS manifestations, UBA1 genotype or VAF, blood counts, or transfusion dependence. Ten patients with PCD also met diagnostic criteria for myelodysplastic syndrome. Cytokines implicated in myeloma pathogenesis were increased in PCD patients, including TNF-α (P = 0.003) and IL-1β (P = 0.002). IL-6, another pro-myeloma and VEXAS cytokine, was elevated in the majority of patients. Immunoglobulin class (n=21) was predominantly IgG λ (43%, n=9) and IgG κ (38%, n=8). PCD-directed FISH identified t(11;14), a translocation between cyclin D1 and immunoglobulin heavy chain locus, as the most common alteration in 41% (7/17). There was aberrant cyclin D1 expression by immunohistochemistry in 50% (11/22). In 8 patients with MM/SMM, 5 had hemoglobin <10g/dL but none had hypercalcemia or renal insufficiency. Monoclonal protein was found in all patients with median M-spike 0.5g/dL (0-1.8). Five patients met MM diagnostic criteria and received plasma cell-directed therapy, including triplet, quadruplet, and high-dose chemotherapy with autologous stem cell rescue with observed clinical responses.
Conclusion: VEXAS patients without PCD demonstrated evidence, orthogonal to clinical observations, of clonal selection: (1) cPCs were identified, (2) cPC expressed higher CCND1 versus pPC, and both higher than healthy, (3) CCND1 and ISG15 functionally connected G2M checkpoint and IFN pathway, both upregulated in VEXAS plasma cells, and (4) canonical pro-myeloma signaling showed stronger cell-cell interactions, including APRIL-BCMA. In summary, our data support a model in which UBA1-mutated plasma cells can persist, but PCD is more likely influenced by inflammatory marrow conditions and clonal selection rather than UBA1 mutation alone, possibly through cyclin D1 mediated pathways.